Introduction {#Sec1}
============

Hepatitis C virus (HCV) related morbidity and mortality places a substantial burden on healthcare systems worldwide^[@CR1],[@CR2]^. While viral hepatitis is the seventh leading cause of death globally, it is the fifth leading cause of death in the Middle East and North Arica (MENA), predominantly due to HCV^[@CR3]^. High HCV antibody prevalence levels are found in few MENA countries^[@CR4],[@CR5]^, mainly in Pakistan, at 4.8%^[@CR6]--[@CR8]^, and Egypt, at 14.7%^[@CR9],[@CR10]^. Recent major breakthroughs in HCV treatment, in the form of Direct Acting Antivirals (DAA), have provided promising prospects for reducing HCV transmission and disease burden^[@CR11],[@CR12]^. Elimination of HCV as a public health problem by 2030 has recently been set as a global target by the World Health Organization (WHO)^[@CR13],[@CR14]^.

While HCV epidemiology in MENA countries, such as Egypt and Pakistan, has been studied in depth^[@CR6],[@CR7],[@CR9],[@CR10],[@CR15]^, HCV epidemiology in Iran remains not well-characterized. Iran is estimated to have the highest population proportion of people who inject drugs (PWID) in MENA^[@CR16]^, a key population at high risk of HCV infection. Iran shares a border with Afghanistan, the world's largest opiates producer^[@CR17]^, and therefore has become a major transit country for drug trafficking^[@CR18]^. Nearly half of opium, heroine, and morphine seizures globally occur in Iran alone^[@CR18]^. Increased availability and lower prices of injectable drugs have led to increased injecting drug use and dependency^[@CR19],[@CR20]^. Understanding HCV epidemiology in Iran is critical for developing and targeting cost-effective and cost-saving prevention and treatment interventions against HCV.

The aim of this study was to characterize HCV epidemiology in Iran by (1) systematically reviewing and synthesizing records, published and unpublished, of HCV incidence and prevalence among the different population groups, (2) systematically reviewing and synthesizing evidence on HCV genotypes, and (3) estimating pooled mean HCV prevalence among the general population and other key risk populations by pooling available HCV prevalence measures. This study is conducted as part of the MENA HCV Epidemiology Synthesis Project, an on-going effort to characterize HCV epidemiology in MENA, providing empirical evidence to inform key public health research, policy, and programming priorities at the national and regional level^[@CR5],[@CR7],[@CR9],[@CR21]--[@CR30]^.

Materials and Methods {#Sec2}
=====================

This study follows the methodology used in the previous systematic reviews of the MENA HCV Epidemiology Synthesis Project^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^. The following subsections summarize this methodology while further details can be found in previous publications of this project^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^.

Data sources and search strategy {#Sec3}
--------------------------------

We systematically reviewed all HCV incidence and prevalence data in Iran as informed by the Cochrane Collaboration Handbook^[@CR31]^. We reported our results using the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines (Table [S1](#MOESM1){ref-type="media"})^[@CR32]^. Our main data sources included PubMed and Embase databases (up to June 27^th^, 2016), the Scientific Information Database (SID) of Iran (up to June 29^th^, 2016), the World Health Organization Index Medicus for the Eastern Mediterranean Region (IMEMR WHO) database (up to July 1^st^, 2016), and the abstract archive of the International Aids Society (IAS) conferences (up to July 1^st^, 2016). Additionally, the MENA HIV/AIDS Epidemiology Synthesis Project database was searched for further records in the form of country level reports and routine data^[@CR33],[@CR34]^. A broad search criteria was used (Fig. [S1](#MOESM1){ref-type="media"}) with no language restrictions. Articles were restricted to those published after 1989, the year in which HCV was first identified^[@CR35],[@CR36]^.

Study selection {#Sec4}
---------------

All records identified through our search were imported into a reference manager, Endnote, where duplicate publications were identified and excluded (Fig. [1](#Fig1){ref-type="fig"}). Similar to our previous systematic reviews^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^, the remaining unique reports underwent two stages of screening, performed by SM and VA. The titles and abstracts were first screened, and those deemed relevant or potentially relevant underwent further screening, in which the full-texts were retrieved and assessed for eligibility, based on our inclusion and exclusion criteria. Eligible reports were included in this study, while the remaining ineligible reports were excluded for reasons indicated in Fig. [1](#Fig1){ref-type="fig"}. The references of all full-text articles and literature reviews were also screened for further potentially relevant reports.Figure 1Flow chart of article selection for the systematic review of hepatitis C virus (HCV) incidence and prevalence in Iran, adapted from the PRISMA 2009 guidelines^[@CR32]^.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

The inclusion and exclusion criteria used were developed based also on our previous systematic reviews^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^. Briefly, any document, of any language, reporting HCV antibody incidence and/or antibody prevalence in Iran, based on biological assays and on primary data, qualified for inclusion in this review. Our exclusion criteria included case reports, case series, editorials, letters to editors, commentaries, literature reviews, and studies reporting HCV prevalence based on self-reporting and/or on Iranian nationals outside of Iran. Studies performed before 1989, and studies referring to HCV as non-A non-B hepatitis, were also excluded. A secondary independent screening was also performed for articles reporting HCV genotype information, regardless of whether information on HCV incidence and/or prevalence was included.

In the subsequent sections, any document including outcome measures of interest will be referred to as a 'report', while details of a specific outcome measure will be referred to as a 'study'. Accordingly, one report may contribute multiple studies, and multiple reports of the same study (outcome measure) were identified as duplicates and considered as one study.

Data extraction and data synthesis {#Sec6}
----------------------------------

Data from relevant reports were extracted by SM and VA. To check for consistency in extractions, 37% of reports were double extracted. Nature of extracted data followed our previous HCV systematic reviews^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^. HCV prevalence measures were rounded to one decimal place, with the exception of those below 1%, which were rounded to two decimal places. Risk factors for HCV infection (at the individual level), which were found to be statistically significant through multivariable regression analyses, were extracted from all articles, when available.

Risk factors for HCV infection were extracted when identified as significant after controlling for confounders through multivariable regression analyses. Data on HCV ribonucleic acid (RNA) prevalence were extracted whenever available in reports including an HCV prevalence measure(s). HCV genotype studies identified through the independent secondary screening were extracted to a separate data file. Extracted data were stratified by study populations' risk of acquiring HCV infection as follows:General populations (that is populations at low risk): these consisted of blood donors, pregnant women, children, healthy adults, and army recruits, among other general population groups.Populations at intermediate risk: these consisted of healthcare workers, household contacts of HCV infected patients, female sex workers, prisoners, homeless people, and drug users (only where the route of drug use *was not specified or excluded drug injection*), among others. Drug users were classified into the intermediate risk category as we could not assess, with the available information, the extent to which drug injection is common in any such specific population---it is possible that the majority of these drug users were not injecting drugs at the time of the study.Populations at high risk: these consisted of HIV patients, PWID, and of populations at high risk of healthcare-related exposures, such as hemodialysis patients, hemophilia patients, thalassemia, patients, and patients with bleeding disorders.Special clinical populations: these consisted of populations with liver-related conditions, such as chronic liver disease, acute viral hepatitis, hepatocellular carcinoma, and liver cirrhosis. This also consisted of other special clinical populations for which the level of HCV risk of exposure could not be ascertained a priori, such as lichen planus patients.

Quantitative assessment {#Sec7}
-----------------------

The quantitative analyses were conducted following an analysis plan similar to that in our previous HCV systematic reviews^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^. HCV prevalence data in reports comprising at least 50 participants were stratified by risk and summarized using reported prevalence measures. Meta-analyses of HCV prevalence measures were conducted by risk category for studies consisting of a minimum of 25 participants. Stratified measures were used in place of HCV prevalence for the total sample only if the sample size requirement was met for each stratum.

A pre-defined sequential order was followed when considering stratifications. Nationality was prioritized, followed by sex, year, region, and age. One stratification was included per study to avoid double-counting.

The variance of the prevalence measures was stabilized using the Freeman-Tukey type arcsine square-root transformation of the corresponding proportions^[@CR37]^. Estimates for HCV prevalence were weighted using the inverse variance method and then pooled using a DerSimonian-Laird random effects model. This model accounts for sampling variation and expected heterogeneity in effect size across studies^[@CR38]^. Heterogeneity was assessed using several measures. The forest plots were visually inspected and Cochran's Q test was conducted, where a p-value \< 0.10 was considered significant^[@CR38],[@CR39]^. The I² and its confidence intervals were calculated^[@CR38]^. The prediction intervals were also calculated to estimate the distribution of true effects around the estimated mean^[@CR38],[@CR40]^.

Univariable and multivariable random-effects meta-regressions, based on established methodology^[@CR31]^, were conducted to determine population-level associations with HCV prevalence and sources of between-study heterogeneity. Variables entered into the univariable model included risk population, sample size (\<100 or ≥100), study site, sampling methodology (probability-based or nonprobability-based), publication year, and median year of data collection. Variables were included into the final multivariable model if the p-value was \<0.10. Variables with a p-value \< 0.05 in the final multivariable meta-regression were considered significant.

The majority of HCV prevalence measures in the general population were among blood donors, a population that mainly includes healthy adults. Therefore, we performed a sensitivity analysis to ascertain the impact of excluding blood donors on our pooled mean estimate for HCV prevalence among the general population (Fig. [S5](#MOESM1){ref-type="media"}).

Descriptive analyses of HCV genotypes and subtypes were also performed. Individuals with mixed HCV genotypes contributed to the quantification of each identified genotype separately. Meta-analyses of genotype proportions were also performed to estimate the pooled mean proportions for each genotype. The diversity of HCV genotypes was assessed using the Shannon Diversity Index^[@CR41]^.

Meta-analyses were performed on R version 3.1.2^[@CR42]^, using the package *meta* ^[@CR43]^. Meta-regressions were performed on STATA 13, using the *metan* command^[@CR44]^.

Qualitative analysis {#Sec8}
--------------------

Similar to our previous HCV systematic reviews^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^, the quality of each incidence or prevalence measure was determined by assessing sources of bias that may affect the reported measure. The Cochrane approach was used to infer the risk of bias (ROB)^[@CR31]^, and the precision of the reported measures was also evaluated. Studies were categorized into low or high ROB based on three quality domains: type of HCV ascertainment (biological assay or otherwise), rigor of sampling methodology (probability-based or nonprobability-based), and response rate (≥80% of the target sample size was reached or otherwise).

Studies with missing information for any of the three domains were categorized as *unclear* ROB for that specific domain. Studies where HCV measures were obtained from individuals presenting voluntarily to facilities where routine blood screening is conducted, or retrieved from patients' medical records, were considered as having *low* ROB on the response rate domain. HCV prevalence measures obtained from country-level routine reporting, with limited description of the methodology used to be able to conduct ROB assessment, were categorized as of *unknown* quality.

Studies where HCV measures were obtained from a sample size of at least 100 individuals were considered as having high precision. For an HCV prevalence of 1% and a sample size of 100, the 95% confidence interval (CI) is 0--5%; a reasonable CI for an HCV prevalence estimate.

Results {#Sec9}
=======

Search results {#Sec10}
--------------

Figure [1](#Fig1){ref-type="fig"} describes the selection process by which studies were included in this systematic review, adapted from the PRISMA flow diagram^[@CR32]^. We identified a total of 3,696 citations: 443 from PubMed, 772 from Embase, 1,885 from SID, 242 from IMEMR WHO, and 354 from the abstract archive of the IAS. After exclusion of duplicates and screening of titles and abstracts, 844 unique reports remained, for which the full-texts were retrieved for full-text screening. After full-text screening, 515 reports were excluded for reasons specified in Fig. [1](#Fig1){ref-type="fig"}. An additional 10 records were identified through screening references of full-text articles and reviews. One country-level report was retrieved and included from the MENA HIV/AIDS Epidemiology Synthesis Project database^[@CR33],[@CR34]^. In total, 340 eligible reports were included in this systematic review. This yielded five HCV incidence measures and 472 HCV prevalence measures.

All 3,696 citations underwent an independent secondary screening for HCV genotype studies (Fig. [S2](#MOESM1){ref-type="media"}). After title and abstract screening and exclusion of duplicates, the full-texts of 144 reports were screened. In total, 44 reports were found eligible for inclusion in this secondary systematic review, yielding 66 HCV genotype measures.

HCV incidence overview {#Sec11}
----------------------

We identified five incidence measures through our search (Table [1](#Tab1){ref-type="table"}), three of which were conducted in Tehran. The highest sero-conversion risks were observed in thalassemia patients and hemodialysis patients, of 6.8% and 4.3%, respectively^[@CR45],[@CR46]^. In special clinical populations, HCV incidence was measured in renal transplant patients and impaired glucose tolerance patients. The HCV sero-conversion risks were 2.1% and 0.71%, respectively^[@CR47],[@CR48]^. In female drug users on methadone treatment (where the route of drug use was not specified) the sero-conversion risk was 2.5%^[@CR49]^. No studies reported incidence rate, nor provided sufficient information for incidence rate to be calculated.Table 1Studies reporting hepatitis C virus (HCV) incidence in Iran.Author, year (citation)Year of data collectionStudy sitePopulation's classification based on risk of HCV exposurePopulationSample size at recruitmentLost to follow-upHCV sero-conversion risk (relative to total sample size)Duration of follow-upPourmand, 2007^[@CR47]^2002--04HospitalSpecial clinical populationRenal transplant patients14102.1%24 monthsJabbari, 2008^[@CR46]^2005--06HospitalHigh risk populationHemodialysis patients7004.3%18 monthsAzarkeivan, 2012^[@CR45]^1996--09Blood transfusion centerHigh risk populationThalassemia patients30706.8%168 monthsDolan, 2012^[@CR49]^2007--08Rehab centerIntermediate risk populationFemale drug users on methadone treatment78382.5%7 monthsBahar, 2007^[@CR48]^1998--01HospitalSpecial clinical populationImpaired glucose tolerance patients56000.71%36 months

HCV prevalence overview {#Sec12}
-----------------------

### General population {#Sec13}

A total of 122 HCV prevalence measures were identified in the general population (Table [2](#Tab2){ref-type="table"}), ranging from 0.0% to 3.1%, with a median of 0.3%. Most measures were obtained from blood donors (n = 72) where HCV prevalence ranged from 0.0% to 3.1%, with a median of 0.3%. In pregnant women (n = 6), HCV prevalence ranged from 0.0% to 0.8%, with a median of 0.3%. In other general populations (n = 44), HCV prevalence ranged from 0.0% to 2.4%, with a median of 0.5%.Table 2Studies reporting hepatitis C virus (HCV) prevalence among the general population (populations at low risk) in Iran.Author, year (citation)Year(s) of data collectionCity or country of surveyStudy siteStudy designStudy sampling procedurePopulationSample sizeHCV prevalence (%)Afzali, 2003^[@CR108]^1996KashanBlood transfusion centerCSNSBlood donors6,6690.37Afzali, 2003^[@CR108]^1997KashanBlood transfusion centerCSNSBlood donors6,7500.64Afzali, 2003^[@CR108]^1998KashanBlood transfusion centerCSNSBlood donors6,9220.59Afzali, 2003^[@CR108]^1999KashanBlood transfusion centerCSNSBlood donors6,9861.6Afzali, 2003^[@CR108]^2001KashanBlood transfusion centerCSNSBlood donors7,7211.7Afzali, 2003^[@CR108]^2000KashanBlood transfusion centerCSNSBlood donors8,6831.5Aghanjanipoor, 2006^[@CR109]^2002BabolBlood transfusion centerCSConvBlood donors16,5760.48Alavi, 2012^[@CR110]^NSTehranNSCCConvHealthy children900.00Alavian, 2002^[@CR111]^1996--1998TehranBlood transfusion centerCCConvBlood donors319,3750.09Alavian, 2015^[@CR112]^2012IsfahanClinical: hospital & health care centersCCConvHealthy adults2750Amini, 2005^[@CR113]^NSTehranBlood transfusion centerCSConvBlood donors1000.00Ansar, 2002^[@CR114]^1997--1998RashtBlood transfusion centerCSSRSBlood donors5,9760.03Ansari-Moghaddam, 2012^[@CR115]^2008--2009ZahedanPrimary health care centers (community)CSCluster samplingResidents (male)1,2070.66Ansari-Moghaddam, 2012^[@CR115]^2008--2009ZahedanPrimary health care centers (community)CSCluster samplingResidents (female)1,3800.36Ardebili, 2012^[@CR116]^2007--2011KavarCommunityCSConvGeneral population6,0950.24Arfaee, 2002^[@CR117]^NSTehranClinical: hospital & health care centersCSConvVeterans3070.97Assarehzadegan, 2008^[@CR118]^2005KhuzestanBlood bankCSConvBlood donors4000.00Babak, 2008^[@CR119]^2006KermanshahCommunityCSCluster samplingResidents1,7210.87Barhaghtalab, 2008^[@CR120]^2002--2007FasaBlood transfusion centerCSConvBlood donors25,4910.55Bozorgi, 2012^[@CR121]^2009GhazvinBlood bankCSConvBlood donors20,5910.17Chamani, 2007^[@CR122]^2004TehranFertility clinic/IVFNSNSInfertile individuals (female)5330.40Chamani, 2007^[@CR122]^2004TehranFertility clinic/IVFCSNSInfertile individuals (male)7160.00Delavari, 2004^[@CR123]^2003KermanBlood transfusion centerCSNSBlood donors (female)2,9210.10Delavari, 2004^[@CR123]^2003KermanBlood transfusion centerCSNSBlood donors (male)12,3310.46Doosti, 2009^[@CR124]^2003--2004Shahre-KordRegional blood transfusion centerCSConvBlood donors11,2000.59Emam, 2006^[@CR125]^2001--2003JahromBlood bankCSConvBlood donors3,0000.30EMRO, 2011^[@CR126]^2011NationalNationalCSConvBlood donors1,986,9920.06Esfandiarpour, 2005^[@CR127]^2002--2003KermanNSCCNSGeneral population1491.3Esmaeili, 2004^[@CR128]^2004BabolClinical: hospital & health care centersCCNSChildren not receiving blood1000.00Esmaeili, 2004^[@CR128]^2004BabolClinical: hospital & health care centersCCNSChildren receiving blood1002.0Esmaeili, 2009^[@CR129]^2006--2007BushehrNSCSConvBlood donors20,2940.21Farajzadeh, 2005^[@CR130]^2001--2002KermanBlood transfusion centerCCConvBlood donors963.1Farshadpour, 2010^[@CR131]^2007--2007AhvazRegional blood transfusion centerCSConvBlood donors2,3762.3Farshadpour, 2016^[@CR132]^2004--2014BushehrBlood transfusion centerCSConvBlood donors293,4540.10Gachkar, 2015^[@CR133]^2004TabrizBlood transfusion centerCSConvBlood donors (male)3990.00Gerayli, 2015^[@CR134]^2012MashhadMedical LaboratoryCCConvHealthy adults1340Ghaderi, 2007^[@CR135]^2004--2006BirjandNSCCConvBlood donors1500.67Ghadir, 2006^[@CR136]^NSGolestanCommunityNSNSGeneral population (male)7360.18Ghadir, 2006^[@CR136]^NSGolestanCommunityNSNSGeneral population (female)1,3870.85Ghafouri, 2011^[@CR137]^2006--2009South KhorasanNSCSConvBlood donors95,5380.01Ghavanini, 2000^[@CR138]^1998ShirazRegional blood transfusion centerCSConvBlood donors7,8790.59Ghezeldasht, 2015^[@CR139]^2009--2010Khorasan RazaviCommunityCSCluster samplingGeneral population1,2270.57Habibzadeh, 2005^[@CR140]^2003ArdabilBlood transfusion centerCSConvBlood donors4410.23Hajiani, 2006^[@CR141]^2003--2004TehranBlood transfusion centerCCNSBlood donors5001.2Hajiani, 2006^[@CR142]^1998--2003AhvazNSCCConvHealthy adults3601.0Heydarabad, 2012^[@CR143]^2010--2012MalekanNSNSNSPregnant women4200.48Hosseien, 2009^[@CR144]^2003--2005TehranRegional blood transfusion centerCSConvBlood donors1,004,8892.1Hosseini, 2007^[@CR145]^2005BoushehrNSNSNSBlood donors19,6270.23Jadali, 2005^[@CR146]^NSTehranNSCCNSHealthy individuals500.00Jadali, 2005^[@CR147]^NSNSNSCCConvHealthy individuals500.00Jamali, 2008^[@CR148]^2006GolestanCommunityCSCluster samplingGeneral population2,0491.0Kafi-abad, 2009^[@CR149]^2004--2007NationalBlood transfusion centerCSConvBlood donors6,499,8510.13Karim, 2008^[@CR150]^2003--2005AhvazBlood transfusion centerCCConvBlood donors1252.4Karimi, 2008^[@CR151]^2004--2006Shahre-KordBlood transfusion centerCSConvBlood donors35,1240.20Kasraian, 2008^[@CR152]^2007--2008ShirazBlood transfusion centerCCConvBlood donors93,9870.21Kasraian, 2010^[@CR153]^2003ShirazBlood transfusion centerPre-postConvBlood donors (post-earthquake)2390.84Kasraian, 2010^[@CR153]^2003ShirazBlood transfusion centerPre-postConvBlood donors (pre-earthquake)1,6940.47Kasraian, 2015^[@CR154]^2002ShirazRegional blood transfusion centerCSConvBlood donorsNS0.19Kasraian, 2015^[@CR154]^2003ShirazRegional blood transfusion centerCSConvBlood donorsNS0.13Kasraian, 2015^[@CR154]^2004ShirazRegional blood transfusion centerCSConvBlood donorsNS0.09Kasraian, 2015^[@CR154]^2005ShirazRegional blood transfusion centerCSConvBlood donorsNS0.16Kavoosi, 2008^[@CR155]^2004--2005KermanshahNSCCConvHealthy adults571.7Kazeminejad, 2005^[@CR156]^2003GorganBlood transfusion centerCSConvBlood donors38,9200.19Keshvari, 2015^[@CR157]^2008TehranBlood transfusion centerCSConvBlood donors296,5670.14Keshvari, 2015^[@CR157]^2013TehranBlood transfusion centerCSConvBlood donors282,0100.07Khedmat, 2007^[@CR158]^2005--2006TehranBlood transfusion centerCSSRSBlood donors1,0142.1Khodabandehloo, 2013^[@CR159]^2008--2011SemnanNSCSConvBlood donors124,7040.03Kordi, 2011^[@CR160]^NSTehranCommunityCCCluster samplingVolleyball and soccer players4100.00Kordi, 2011^[@CR160]^NSTehranCommunityCCCluster samplingWrestlers (male)4200.48Mahmoudian, 2006^[@CR161]^2003--2004Mixed (28 provinces unspecified)Blood transfusion centerCSConvBlood donors1,489,9350.07Maneshi, 2010^[@CR162]^2004--2008BushehrBlood transfusion centerCSConvBlood donors51,8840.33Mansour-Ghanaei, 2007^[@CR163]^1998--2003GuilanBlood transfusion centerCSConvBlood donors221,5080.32Masaeli, 2006^[@CR164]^2002--2003IsfahanBlood transfusion centerCSConvBlood donors29,4580.24Merat, 2010^[@CR54]^2006Mixed (Golestan, Tehran, Hormozgan)CommunityCSCluster samplingGeneral population5,6840.88Metanet, 2006^[@CR165]^2004ZahedanNSCCConvBlood donors1,3990.07Moezzi, 2015^[@CR166]^NSChaharmahal and BakhtiariCommunityCSSingle stage cluster samplingAdults3,0001.4Mogaddam, 2010^[@CR167]^NSArdabilBlood bankCCNSBlood donors600.00Mohammadali, 2014^[@CR168]^2005--2011TehranBlood transfusion centerCSConvBlood donors2,031,4510.39Mohebbi, 2011^[@CR169]^2007--2008LorestanPrimary health care centers (community)CSConvPregnant women8270.24Moniri, 2004^[@CR170]^2001--2002KashanBlood bankCSConvBlood donors6000.50Monsour-Ghanaei, 2007^[@CR73]^2003GuilanCommunityCSConvResidents of nursing home3832.3Moradi, 2007^[@CR171]^2001--2002Saravan city, Sistan and BaluchistanCommunityCSCluster samplingWomen in childbearing ages3560.84Motlagh, 2001^[@CR172]^1999--2000AhvazNSCSConvPregnant women800.00Mousavi, 2010^[@CR173]^2008KhuzestanClinical setting (hospital)CSConvRenal transplant donors790.00Mousavi, 2011^[@CR174]^2009--2010AhvazClinical setting (hospital)CSConvRenal transplant donors520.00Pourshams, 2005^[@CR175]^2001TehranBlood bankCSSRSBlood donors1,9590.46Poustchi, 2011^[@CR56]^NSGolestanCommunityCSCluster samplingGeneral population49,3380.50Rahbar, 2004^[@CR176]^2001--2002MashhadBlood transfusion centerCSNSBlood donors60,8920.10Rahnama, 2005^[@CR177]^2000--2001KermanRegional blood transfusion centerCCSRSBlood donors1402.1Razjou, 2012^[@CR178]^2009NationalBlood bankCSConvBlood donors1,494,2820.13Rezaie, 2016^[@CR179]^2011--2015SemnanBlood transfusion centerCSConvBlood donors42,2530.06Rezazadeh, 2006^[@CR180]^2004--2005HamadanBlood transfusion centerCSConvBlood donors18,3060.43Roshan, 2012^[@CR181]^2007--2008AhvazFertility clinic/IVFCSConvInfertile couples (male)7120.84Roshan, 2012^[@CR181]^2007--2008AhvazFertility clinic/IVFCSConvInfertile couple (female)7120.42Salehi, 2011^[@CR182]^2002--2006IsfahanClinical: hospital & health care centersCSConvBlood donors4,8080.27Samadi, 2014^[@CR183]^2012AhvazBlood transfusion centerCSConvBlood donors2,1080.00Seyed-Askari, 2015^[@CR184]^2009--2013KermanBlood transfusion centerCSConvBlood donors360,7220.08Shaheli, 2015^[@CR185]^2012ShirazCommunityCCConvHealthy adults1000Shahshahani, 2013^[@CR186]^2004--2010YazdBlood transfusion centerCSConvBlood donors346,4710.07Shakeri, 2013^[@CR187]^2010--2011MashhadCommunityCSCluster samplingGeneral population3,8700.13Shamsdin, 2012^[@CR188]^2010--2011ShirazCommunityCSConvGeneral population2,0800.72Sofian, 2010^[@CR189]^2008ArakRegional blood transfusion centerCSSRSBlood donors5310.19Sohrabpour, 2010^[@CR190]^NSMixed (Hormozgan, Tehran, Golestan)CommunityCSCluster samplingGeneral population5,5890.88Tahereh, 2005^[@CR191]^2000--2002GhazvinBlood transfusion centerCSSRSBlood donors39,5980.25Taheri, 2008^[@CR192]^2003--2005RashtBlood transfusion centerCSConvBlood donors49,8200.18Tajbakhsh, 2007^[@CR193]^2004ShahrekordBlood transfusion centerCSConvBlood donors11,4720.60Tanomand, 2007^[@CR194]^2005Malekan cityClinical setting (hospital)CSSRSGeneral population3460.29Vahidi, 2000^[@CR195]^1996KermanClinical setting (hospital)CCConvHealthy children1070.00Yazdani, 2006^[@CR196]^1998--2000KermanshahClinical setting (hospital)CSConvPregnant women2,0000.60Zamani, 2013^[@CR197]^2008--2011MazandaranPrimary health care centers (community)CSCluster samplingGeneral population6,1450.08Zanjani, 2013^[@CR198]^2005--2006ZanjanBlood transfusion centerCSConvBlood donors297160.11^a^Abbreviations: CC, case-control; Conv, convenience; CS, cross-sectional; EMRO, Eastern Mediterranean Regional Office (WHO); IVF, *in vitro* fertilization; NS, not specified, SRS; simple random sampling.^b^The decimal places of the prevalence figures are as reported in the original reports, but prevalence figures with more than one decimal places were rounded to one decimal place, with the exception of those below 1%.

### Populations at high risk {#Sec14}

A total of 208 HCV prevalence measures were identified in populations at high risk (Table [3](#Tab3){ref-type="table"}), ranging from 0.0% to 90.0%, with a median of 26.3%. The majority were conducted on high risk clinical populations (n = 127). In hemophilia patients (n = 25), HCV prevalence ranged from 6.0% to 90.0%, with a median of 54.0%. In thalassemia patients (n = 58), HCV prevalence ranged from 0.0% to 68.9%, with a median of 16.6%. In hemodialysis patients (n = 41), HCV prevalence ranged from 0.0% to 31.4%, with a median of 8.3%. In HIV positive patients (n = 25), HCV prevalence ranged from 3.9% to 89.3%, with a median of 67.7%. Among PWID (n = 56), HCV prevalence ranged from 11.3% to 88.9%, with a median of 51.4%.Table 3Studies reporting hepatitis C virus (HCV) prevalence among populations at high risk in Iran.Author, year (citation)Year(s) of data collectionCity or country of surveyStudy siteStudy designStudy sampling procedurePopulationSample sizeHCV prevalence (%)Abdollahi, 2008^[@CR199]^2003NSHemophilia unitsCSConvHemophilia patients17483.3Aghakhani, 2009^[@CR200]^NSTehranNSCSConvHIV patients10667.0Aghakhani, 2009^[@CR200]^NSTehranNSCSConvHemodialysis patients2893.1Akbari, 2011^[@CR201]^2003--2004ShirazThalassemia centerCCSRSThalassemia patients20025.0Alavi, 2005^[@CR202]^2002TehranClinical: hospital & health care centersCSConvThalassemia patients11011.8Alavi, 2007^[@CR203]^2001--2003AhvazClinical: hospital & health care centersCSConvPWID with HIV10474.0Alavi, 2009^[@CR204]^2001--2006AhvazClinical: hospital & health care centersCSConvPWID14252.1Alavi, 2012^[@CR110]^NSTehranClinical: hospital & health care centersCCConvThalassemia patients (\<18)9013.3Alavia, 2003^[@CR205]^NSGhazvinClinical: hospital & health care centersNSNSThalassemia patients9524.2Alavian, 2003^[@CR206]^2000--2001NSHemophilia unitsCSConvHemophilia patients17660.2Alavian, 2008^[@CR94]^1999NationalNSNSNSHemodialysis patientsNS14.4Alavian, 2008^[@CR94]^2000NationalNSNSNSHemodialysis patientsNS11.2Alavian, 2008^[@CR94]^2001NationalNSNSNSHemodialysis patientsNS8.8Alavian, 2008^[@CR94]^2002NationalNSNSNSHemodialysis patientsNS8.2Alavian, 2008^[@CR94]^2003NationalNSNSNSHemodialysis patientsNS6.7Alavian, 2008^[@CR94]^2004NationalNSNSNSHemodialysis patientsNS5.6Alavian, 2008^[@CR94]^2005NationalNSNSNSHemodialysis patientsNS4.8Alavian, 2008^[@CR94]^2006NationalNSNSNSHemodialysis patientsNS4.5Alavian, 2015^[@CR112]^2012IsfahanHemodialysis unitsCCConvHemodialysis units2740Alipour, 2013^[@CR61]^2003--2011ShirazCounseling centersCSConvHIV patients (male)21517.7Alipour, 2013^[@CR61]^2003--2011ShirazCounseling centersCSConvHIV patients (female)1,23089.1Alipour, 2013^[@CR207]^NSMixed (Shiraz, Tehran, Mashhad)Drop in centers and rehab centersCSConvPWID (male)22638.6Alipour, 2013^[@CR67]^2011ShirazCounseling centersCSSRSHIV patients16887.5Alizadeh, 2005^[@CR208]^2002HamedanPrisonCSSRSPWID14931.5Alizadeh, 2006^[@CR209]^NSHamadanClinical: hospital & health care centersCSNSHemophilia patients6659.1Ameli, 2008^[@CR210]^2006MazandaranClinical: hospital & health care centersCSConvThalassemia patients6516.9Amin-Esmaeili, 2012^[@CR57]^2006--2007TehranDrop in centers and rehab centersCSConvPWID89534.5Amiri, 2005^[@CR211]^2001GuilanHemodialysis unitsCSConvHemodialysis patients29824.8Ansar, 2002^[@CR114]^1997--1998RashtClinical: hospital & health care centersCSSRSThalassemia patients (female)5062.0Ansar, 2002^[@CR114]^1997--1998RashtClinical: hospital & health care centersCSSRSThalassemia patients (male)5565.0Ansar, 2002^[@CR114]^1997--1998RashtClinical: hospital & health care centersCSSRSHemophilia patients9355.9Ansari, 2007^[@CR212]^2005--2006ShirazClinical: hospital & health care centersCSConvThalassemia patients (female)40016.0Ansari, 2007^[@CR212]^2005--2006ShirazClinical: hospital & health care centersCSConvThalassemia patients (male)40612.8Asl, 2013^[@CR213]^2003--2005AlborzPrisonsCohConvPWID15069.3Assarehzadegan, 2012^[@CR214]^2008--2009AhvazClinical: hospital & health care centersCSConvHemophilia patients8754.0Ataei, 2010^[@CR215]^2008--2009IsfahanDrop in centers and rehab centersCSConvPWID3,28438.0Ataei, 2010^[@CR53]^1998--2007IsfahanClinical: hospital & health care centersCSConvHIV patients13077.0Ataei, 2011^[@CR216]^NSIsfahanPrison, drop in centers and rehab centersCSConvPWID1,48543.4Ataei, 2011^[@CR217]^NSIsfahanDrop in centers and rehab centersCSConvPWID13619.8Ataei, 2012^[@CR218]^1996--2011IsfahanClinical: hospital & health care centersCSConvThalassemia patients4638.0Azarkeivan, 2010^[@CR219]^1996--2005TehranThalassemia centerCSConvThalassemia patients39527.5Azarkeivan, 2011^[@CR220]^2008TehranThalassemia centerCSConvThalassemia patients69524.5Azarkeivan, 2012^[@CR45]^1996--2009TehranClinical: hospital & health care centersCohConvThalassemia patients3957.6Babamahmoodi, 2012^[@CR221]^2008--2010MazandaranClinical: hospital & health care centersCSConvHIV patients8058.8Basiratnia, 2010^[@CR222]^1999ShahrekordClinical: hospital & health care centersNSNSThalassemia patients (female)5022.0Basiratnia, 2010^[@CR222]^1999ShahrekordClinical: hospital & health care centersNSNSThalassemia patients (male)6323.8Boroujerdnia, 2009^[@CR223]^2006--2007KhuzestanClinical: hospital & health care centersCSConvThalassemia patients20628.1Bozorghi, 2006^[@CR224]^2004GhazvinClinical: hospital & health care centersCSConvHemodialysis patients896.7Bozorgi, 2008^[@CR225]^2005GhazvinClinical: hospital & health care centersCSConvThalassemia patients20724.2Broumand, 2002^[@CR226]^NSTehranHemodialysis unitsCSConvHemodialysis patients54819.6Company, 2007^[@CR227]^2005--2006AhvazClinical: hospital & health care centersCSConvThalassemia patients19520.5Dadgaran, 2005^[@CR228]^NSGuilanHemodialysis unitsNSNSHemodialysis patients39317.8Dadmanesh, 2015^[@CR229]^2012--2013TehranClinical: hospital & health care centersCSConvHemodialysis patients1380Davarpanah, 2013^[@CR230]^2006--2007ShirazCounseling centersCSConvHIV patients22686.7Davoodian, 2009^[@CR231]^2002TehranPrisonsCSSRSPWID24964.8Eghbalian, 2000^[@CR232]^NSHamedanClinical: hospital & health care centersCSNSThalassemia patients (\<15)5334.0Esfahani, 2014^[@CR233]^2012HamedanHemophilia unitsCSConvHemophilia patients8949.4Eskandarieh, 2013^[@CR234]^NSTehranDrop in centers and rehab centersCSConvPWID25865.9Eslamifar, 2007^[@CR235]^2006TehranHemodialysis unitsCSConvHemodialysis patients776.5Etminani-Esfahani, 2012^[@CR236]^NSTehranClinical: hospital & health care centersCSConvHIV patients9855.1Faramarzi, 2013^[@CR237]^2010ShirazVoluntary counseling centerCSConvHIV patients (male)22264.0Faranoush, 2006^[@CR238]^2002Mixed (Semnan, Damaghan, Garmsar)Clinical: hospital & health care centersCSConvThalassemia patients63039.7Farhoudi, 2016^[@CR239]^2013--2014TehranPrisonCSConvHIV patients5689.3Ghaderi, 1996^[@CR240]^NSFarsBlood transfusion centerCSConvThalassemia patients9068.5Ghadir, 2009^[@CR241]^2008QomHemodialysis unitsCSConvHemodialysis patients9021.1Ghafoorian-Broujerdnia, 2006^[@CR242]^1999--2004AhvazClinical: hospital & health care centersCSConvThalassemia patients12226.2Ghane, 2012^[@CR243]^2010Mixed (Mazandaran and Guilan)Clinical: hospital & health care centersCSConvThalassemia patients24514.7Haghazali, 2011^[@CR244]^2007GhazvinClinical: hospital & health care centersCSConvHemodialysis patients (males)767.5Hamissi, 2011^[@CR245]^2009GhazvinClinical: hospital & health care centersCSConvHemodialysis patients1956.7Hariri, 2006^[@CR246]^2004IsfahanClinical: hospital & health care centersCSConvHemophilia patients12064.0Hariri, 2006^[@CR246]^2004IsfahanClinical: hospital & health care centersCSConvThalassemia patients61610.9Honarvar, 2013^[@CR247]^2012--2013ShirazDrop in centers and rehab centersCSConvPWID23340.3Hosseini, 2010^[@CR63]^2006TehranPrisonCSConvPWID41780.0Imani, 2008^[@CR248]^2004Shahr-e-KordDrop in centers and rehab centersCSConvPWID13311.3Ismail, 2005^[@CR249]^NSTehranClinical: hospital & health care centersCSConvPWID6517.0Jabbari, 2008^[@CR46]^2005--2006GolestanClinical: hospital & health care centersCSConvHemodialysis patients9324.7Joukar, 2011^[@CR250]^2009GuilanHemodialysis unitsCSConvHemodialysis patients51411.9Kaffashian, 2011^[@CR251]^NSIsfahanPrisonCSConvPWID95142.0Kalantari, 2011^[@CR252]^2008--2010IsfahanClinical: hospital & health care centersCSConvThalassemia patients5459.1Kalantari, 2011^[@CR252]^2008--2010IsfahanClinical: hospital & health care centersCSConvHemophilia patients61580.5Kalantari, 2014^[@CR253]^2010--2011IsfahanHemodialysis unitsCSCluster samplingHemodialysis patients4995.2Karimi, 2001^[@CR254]^1999--2001ShirazThalassemia centerCSConvThalassemia patients46615.7Karimi, 2001^[@CR255]^1999--2001ShirazHemophilia unitCSConvHemophilia patients28115.7Karimi, 2002^[@CR256]^2002ShirazClinical: hospital & health care centersCSConvCoagulation disorder patients36713.1Kashef, 2008^[@CR257]^NSTabrizClinical: hospital & health care centersCSConvThalassemia patients13118.3Kassaian, 2011^[@CR258]^2009IsfahanThalassemia centerCSConvThalassemia patients57010.5Kassaian, 2011^[@CR258]^2009IsfahanHemodialysis unitCSConvHemodialysis patients8002.1Kassaian, 2012^[@CR58]^2009IsfahanPrisonCSConvPWID94341.6Keramat, 2011^[@CR259]^2005--2007HamadanCounseling centerCSConvPWID19963.3Keshvari, 2014^[@CR260]^2008--2010TehranThalassemia centerCSConvThalassemia patients25740.1Khani, 2003^[@CR261]^2001ZanjanPrisonCSConvPWID34650.9Kheirandish, 2009^[@CR52]^2006TehranPrisonCSConvPWID45480.0Khorvash, 2008^[@CR262]^2005IsfahanClinical: hospital & health care centersCSConvPWID9274.3Khosravi, 2010^[@CR263]^NSShirazCounseling centerCSConvHIV patients10186.1Kiakalayeh, 2013^[@CR264]^2002--2011RashtClinical: hospital & health care centersCSConvThalassemia patients1,11310.5Lak, 2000^[@CR265]^NSTehranHemophilia unitsCSConvHemophilia patients10090.0Lak, 2000^[@CR265]^NSTehranClinical: hospital & health care centersCSConvVWD patient38555.1Langarodi, 2011^[@CR266]^2009--2010KarajClinical: hospital & health care centersCSConvThalassemia patients20614.1Mahdaviani, 2008^[@CR267]^2004MarkaziClinical: hospital & health care centersCSConvHemophilia patients6836.7Mahdaviani, 2008^[@CR267]^2004MarkaziClinical: hospital & health care centersCSConvThalassemia patients977.2Mahdavimazdeh, 2009^[@CR268]^2005TehranHemodialysis unitsCSConvHemodialysis patients2,4039.5Mak, 2001^[@CR269]^NSIsfahanHemodialysis unitsCSConvHemodialysis patients8631.1Makhlough, 2008^[@CR270]^2006Sari and Ghaemshahr, MazandaranHemodialysis unitsCSConvHemodialysis patients18611.3Mansour-Ghanaei,2002^[@CR271]^1999GuilanHemophilia unitsCSConvHemophilia patients10171.3Mansour-Ghanaei,2009^[@CR272]^2007RashtClinical: hospital & health care centersCSConvHemodialysis patients16310.4Mansour-Ghanaei,2009^[@CR273]^NSGuilanThalassemia centerCSConvThalassemia patients37050.4Mashayekhi, 2011^[@CR274]^2008--2009TabrizThalassemia centerCSConvThalassemia patients1003.0Mehrjerdi, 2014^[@CR68]^2011TehranDrop in centers and rehab centersCSConvPWID20926.8Meidani, 2009^[@CR275]^2007--2008IsfahanClinical: hospital & health care centersCSConvPWID15026.0Mirahmadizadeh, 2004^[@CR276]^NSShirazNSCSNSPWID18680.1Mirahmadizadeh, 2009^[@CR277]^NSNationalDrop in centers and rehab centersCSSRSPWID1,53143.4Mirmomen, 2006^[@CR278]^2002Mixed (Tehran, Kerman, Ghazvin, Semnan, Zanjan)Blood transfusion centersCSConvThalassemia patients73219.6Mir-Nasseri, 2005^[@CR62]^2001--2002TehranDrop in centers and rehab centersCSNSPWID46766.0Mir-Nasseri, 2011^[@CR55]^2001--2002TehranPrison, drop in centers and rehab centersCSConvPWID51869.3Mobini, 2010^[@CR279]^2006YazdClinical: hospital & health care centersCSConvHemophilia patients7749.4Mohammadi, 2009^[@CR280]^2007--2008LorestanNSCSConvHIV patients39172.1Momen-Heravi, 2012^[@CR281]^NSKashanDrop in centers and rehab centersCSCluster samplingPWID30047.3Mousavi, 2002^[@CR282]^NSNSNSNSNSThalassemia patients8127.2Mousavian, 2011^[@CR283]^2003--2005TehranHemophilia unitsCSConvHemophilia patients1,09572.3Naini, 2007^[@CR284]^1993--2006IsfahanHemophilia unitsCSConvHemophilia patients55322.6Najafi, 2001^[@CR285]^1998QaemshahrThalassemia centersCSConvThalassemia patients10018.0Rahbar, 2004^[@CR176]^2001MashhadPrisonCCConvPWID10159.4Rahimi-Movaghar, 2010^[@CR286]^2006--2007TehranDrop in centers and rehab centersCSSnowball samplingPWID89934.5Ramezani, 2008^[@CR287]^2005--2006TehranCounseling centerCSConvHIV patients17152.6Ramezani, 2009^[@CR288]^NSTehranClinical: hospital & health care centersCSConvHIV patients9168.5Ramzani, 2014^[@CR289]^2012ArakDrop in centers and rehab centersCSConvPWID10056.0Rostami, 2013^[@CR290]^2010--2011MixedHemodialysis unitsCSConvHemodialysis patients39631.3Rostami-Jalilian, 2006^[@CR291]^2002--2004IsfahanClinical: hospital & health care centersCSConvPWID with thrombosis7245.8Rostami-Jalilian, 2006^[@CR291]^2002--2004IsfahanClinical: hospital & health care centersCSConvPWID without thrombosis7634.2Sabour, 2003^[@CR292]^1999--2000KermanshahClinical: hospital & health care centersCSConvHemodialysis patients14026.4Saleh, 2011^[@CR293]^2007--2008HamedanClinical: hospital & health care centersCCConvPWID (corpses)9460.6Salehi, 2015^[@CR69]^2006--2011ShirazDrop in centers and rehab centersCSConvPWID1,32713.5Sali, 2013^[@CR294]^2010--2012TehranClinical: hospital & health care centersCSConvHIV patients20071.0Samak, 2012^[@CR295]^2007QomClinical: hospital & health care centersCSConvThalassemia patients14213.4Samarbaf-Zadeh, 2015^[@CR296]^NSKhuzestanClinical: hospital & health care centersCSConvHemodialysis patients4309.1Samimi-Rad, 2007^[@CR297]^2004MarkaziClinical: hospital & health care centersCSConvThalassemia patients (male)504.0Samimi-Rad, 2007^[@CR297]^2004MarkaziClinical: hospital & health care centersCSConvPatients with Inherited bleeding disorder7643.4Samimi-Rad, 2007^[@CR298]^2005IsfahanClinical: hospital & health care centersCSConvHemophilia patients50100.0Samimi-Rad, 2007^[@CR298]^2005IsfahanClinical: hospital & health care centersCSConvThalassemia patients53100.0Samimi-Rad, 2008^[@CR299]^2005MarkaziHemodialysis unitsCSConvHemodialysis patients2044.9Sanei, 2004^[@CR300]^2002ZahedanClinical: hospital & health care centersCSConvThalassemia patients36413.5Sani, 2012^[@CR301]^2007--2009MashhadClinical: hospital & health care centersCSConvPWID6271.0Sarkari, 2012^[@CR59]^2009--2010Mixed (Kohgiloyeh and Boyerahmad)NSCSConvPWID15842.2SeyedAlinaghi, 2011^[@CR302]^2004--2005TehranClinical: hospital & health care centersCSConvHIV patients20167.2Seyrafian, 2006^[@CR303]^2005IsfahanHemodialysis unitsCSConvHemodialysis patients5562.9Shahshahani, 2006^[@CR304]^NSYazdNSCSNSHemophilia patients7448.6Shahshahani, 2006^[@CR304]^NSYazdNSCSNSThalassemia patients859.4Sharif, 2009^[@CR305]^2001--2006KashanClinical: hospital & health care centersCSConvPWID20012.0Sharifi-Mood, 2006^[@CR306]^1986--2005ZahedanHemophilia unitsCSConvHemophilia patients7431.1Sharifi-Mood, 2007^[@CR307]^2003--2006ZahedanHemophilia unitsCSConvHemophilia patients8129.6Siavash, 2008^[@CR308]^2007KermanshahClinical: hospital & health care centersCSConvHIV patients8883.9Sofian, 2012^[@CR309]^2009MarkaziPrisonCSConvPWID15359.5Somi, 2007^[@CR310]^2006TabrizHemodialysis unitsCSConvHemodialysis patients46214.9Somi, 2014^[@CR311]^2012TabrizHemodialysis unitsCSConvHemodialysis patients4558.1Taremi, 2005^[@CR312]^2004TabrizHemodialysis unitsCSConvHemodialysis patients32420.4Tayeri, 2008^[@CR313]^2000--2007IsfahanClinical: hospital & health care centersCSConvPWID with HIV10675.5Taziki, 2008^[@CR314]^2001MazandaranHemodialysis unitsCSConvHemodialysis patients34818.0Taziki, 2008^[@CR314]^2006MazandaranHemodialysis unitsCSConvHemodialysis patients49712.0Toosi, 2007^[@CR315]^NSTehranClinical: hospital & health care centersCSConvHemodialysis patients1308.5Torabi, 2005^[@CR316]^2003AzerbaijanClinical: hospital & health care centersCSConvThalassemia patients (\<18)847.1Torabi, 2006^[@CR317]^2003AzerbaijanClinical: hospital & health care centersCSConvHemophilia patients13055.4Vahidi, 2000^[@CR195]^1996KermanClinical: hospital & health care centersCCConvThalassemia patients10722.4Valizadeh, 2013^[@CR318]^2010UrmiaHemophilia unitsCSConvHemophilia patients506.0Yazdani, 2012^[@CR319]^1996--2010IsfahanHemophilia unitsCSConvHemophilia patients35066.0Zadeh, 2007^[@CR320]^2007TehranNSCSConvPWID (males)7036.0Zahedi, 2004^[@CR321]^2002KermanClinical: hospital & health care centersCSConvHemophilia patients9744.3Zahedi, 2012^[@CR322]^2010KermanHemodialysis centersCSConvHemodialysis patients2283.0Zali, 2001^[@CR323]^1995TehranPrisonCSSRSPWID (male)40245.0Zamani, 2007^[@CR51]^2004TehranCommunity, drop in centers and rehab centersCSConvPWID20252.0Zamani, 2010^[@CR64]^2008Foulad-Shahr CityDrop in centers and rehab centersCSSnowball samplingPWID11760.7Ziaee, 2005^[@CR324]^2000KhorasanDrop in centers and rehab centersCSConvHemophilia patients8055.0Ziaee, 2007^[@CR325]^NSSouth KhorassanHemophilia unitsCSConvHemophilia patients8026.3Ziaee, 2015^[@CR326]^2010--2012BirjandHemophilia unitsCSConvHemophilia patients10820.4^a^Abbreviations: CC, case-control; Coh, cohort; Conv, convenience; CS, cross-sectional; NS, not specified; PWID, people who inject drugs; SRS, simple random sampling; VWD, von Willebrand disease.^b^The decimal places of the prevalence figures are as reported in the original reports, but prevalence figures with more than one decimal places were rounded to one decimal place, with the exception of those below 1%.

### Populations at intermediate risk {#Sec15}

A total of 70 HCV prevalence measures were identified in intermediate risk populations (Table [S2](#MOESM1){ref-type="media"}), ranging from 0.0% to 48.0%, with a median of 3.3%. In prisoners (n = 15), HCV prevalence ranged from 0.7% to 37.9%, with a median of 4.1%. In homeless people (n = 10), HCV prevalence ranged from 0.0% to 48.0%, with a median of 3.0%. Half of these studies were conducted on homeless children, among which HCV prevalence ranged from 0.0% to 3.5%, with a median of 1.0%. In household contacts of HCV index patients (n = 5), HCV prevalence ranged from 0.0% to 3.3%, with a median of 2.2%. In healthcare workers (n = 11), HCV prevalence ranged from 0.0% to 37.0%, with a median of 0.0%. In drug users (where the route of drug use was not specified (n = 13), HCV prevalence ranged from 3.4% to 36.1%, with a median of 14.5%.

### Special clinical populations {#Sec16}

A total of 72 HCV prevalence measures were identified in special clinical populations (Table [S3](#MOESM1){ref-type="media"}), ranging from 0.0% to 69.1%, with a median of 3.2%. In hepatitis B virus patients, prevalence ranged from 0.0% to 18.0%, with a median of 10.3%. In viral hepatitis patients (n = 9), HCV prevalence ranged from 0.0% to 34.9%, with a median of 6.1%. In patients with liver cirrhosis (n = 5), HCV prevalence ranged from 1.7% to 14.9%, with a median of 7.3%.

Pooled mean HCV prevalence estimates {#Sec17}
------------------------------------

Table [4](#Tab4){ref-type="table"} shows the results of our meta-analyses for HCV prevalence. The estimated national population-level HCV prevalence, based on the pooled HCV prevalence in the general population, was 0.3% (95% CI: 0.2--0.4%). There was significant evidence of heterogeneity (p \< 0.0001). I^2^ was estimated at 99.8% (95% CI: 99.8--99.8%), indicating that almost all observed variation is attributed to true variation in HCV prevalence rather than sampling error. The prediction interval was 0.0--1.5%.Table 4Results of the meta-analyses for hepatitis C virus (HCV) prevalence measures in Iran stratified by populations' risk of exposure.Population at riskStudiesSamplesHCV prevalenceHeterogeneity measuresTotal NTotal nRange (%)Mean (%)95% CIQ (p-value)ªI² (confidence limits)^c^Prediction interval (%)^d^General population (populations at low risk)12216,073,4790.0--3.10.30.2--0.456269.6 (p \< 0.0001)99.8% (99.8--99.8%)0.0--1.5Populations at high risk20855,2570.0--90.032.128.1--36.2217272.1 (p \< 0.0001)99.0% (99.0--99.1%)0.0--88.5    PWID5617,99911.3--88.952.246.9--57.52615 (p \< 0.0001)97.9% (97.6--98.1%)15.8--87.3    Populations at high risk of healthcare-related exposures12732,5170.0--90.020.016.4--23.98786.2 (p \< 0.0001)98.6% (98.5--98.8%)0.0--69.7Populations at intermediate risk7036,8790.0--48.06.23.4--9.69,128 (p \< 0.0001)99.2% (99.2--99.3%)0.0--49.9Special clinical populations7255,1870.0--69.14.63.2--6.12293.6 (p \< 0.0001)96.9% (96.5--97.3%)0.0--21.6 Populations with liver-related conditions286,3380.0--34.97.54.3--11.4639.5 (p \< 0.0001)95.8% (94.8--96.6%)0.0--35.2    Other special clinical populations4448,8490.0--69.12.71.8--3.6520.6 (p \< 0.0001)91.7% (89.8--93.3%)0.0--9.6^a^Abbreviations: CI, confidence interval.^b^Q: Cochran Q statistic assessing the existence of heterogeneity in HCV prevalence estimates.^c^I²: a measure assessing the magnitude of between-study variation that is due to difference in HCV prevalence estimates across studies rather than chance.^d^Prediction interval: a measure estimating the 95% interval in which the true HCV prevalence in a new HCV study will lie.

The pooled mean HCV prevalence for populations at high risk was 32.1% (96% CI: 28.1--36.2%). There was significant evidence of heterogeneity (p \< 0.0001), with an I^2^ of 99.0% (95% CI: 99.0--99.1%). The prediction interval was 0.0--88.5%. For the subpopulations of PWID and populations at high risk of healthcare-related exposures, the pooled means were 52.2% and 20.0%, respectively.

The pooled mean HCV prevalence for populations at intermediate risk was 6.2% (95% CI: 3.4--9.6%). There was significant evidence of heterogeneity (p \< 0.0001), with an I^2^ of 99.2% (95% CI: 99.2--99.3%). The prediction interval was 0.0--49.9%.

The pooled mean HCV prevalence for special clinical populations was 4.6% (95% CI: 3.2--6.1%). There was significant evidence of heterogeneity (p \< 0.0001), with an I^2^ of 96.9% (95% CI: 96.5--97.3%). The prediction interval was 0.0--21.6%. For the subpopulations of populations with liver-related conditions and other special clinical populations, the pooled means were 7.5% and 2.7%, respectively.

The forest plots for the HCV prevalence meta-analyses can be found in Figs [S3](#MOESM1){ref-type="media"} and [S4](#MOESM1){ref-type="media"}.

Sensitivity analysis {#Sec18}
--------------------

After excluding blood donor data, the national population-level HCV prevalence was estimated at 0.3% (95% CI: 0.2--0.5%). There was significant evidence of heterogeneity (p \< 0.0001), with an I^2^ of 76.3% (95% CI: 67.5--81.7%). The prediction interval was 0.0--1.3%. The forest plot for this sensitivity analysis can be found in Fig. [S5](#MOESM1){ref-type="media"}.

HCV RNA prevalence {#Sec19}
------------------

Our search identified a total of 55 HCV RNA measures. The details of each of these measures can be found in Table [S4](#MOESM1){ref-type="media"}. These were reported either among HCV antibody positive individuals, or as a proportion of the entire sample. HCV RNA prevalence among HCV antibody positive individuals ranged from 0% to 89.3%, with a median of 61.9%. HCV RNA prevalence as a proportion of the entire sample ranged from 0% to 60.0%, with a median of 8.6%. HCV RNA prevalence as a proportion of the entire sample was high in several populations at high risk of healthcare-related exposures.

Risk factors for HCV infection {#Sec20}
------------------------------

A number of studies assessed risk factors for HCV exposure using multivariable regression analyses. Risk factors most commonly reported included history and duration of incarceration and multiple incarcerations^[@CR50]--[@CR62]^, history and duration of intravenous drug use^[@CR50],[@CR51],[@CR54],[@CR57],[@CR58],[@CR60]--[@CR67]^, history of sharing a needle or syringe^[@CR55],[@CR57],[@CR62],[@CR68],[@CR69]^, history of tattooing^[@CR50]--[@CR52],[@CR61],[@CR70],[@CR71]^, history of sharing razors^[@CR67]^, multiple sex partners^[@CR57],[@CR58],[@CR66],[@CR67],[@CR69],[@CR70],[@CR72]^, being a man who have sex with men^[@CR54],[@CR62],[@CR68],[@CR73]^, history of surgery^[@CR70],[@CR73]^, history of blood transfusion^[@CR56],[@CR60],[@CR73]^, and history of hemodialysis^[@CR74]^.

HCV genotypes {#Sec21}
-------------

HCV genotype data was identified in 66 studies including a total of 24,029 HCV RNA positive individuals. Of these, 895 individuals had an undetermined genotype and were therefore excluded from further analysis. The vast majority of individuals were infected by a single genotype, with only 2.9% being infected by multiple genotypes. The proportion of infections for each HCV genotype was highest in genotype 1 (58.2%), followed by genotype 3 (39.0%), genotypes 2 (1.7%), and genotype 4 (1.0%).

The pooled mean proportion for genotype 1 was 56.3% (95% CI: 52.9--59.6%), genotype 3 was 38.8% (95% CI: 35.7--41.9%), genotype 2 was 0.4% (95% CI: 0.0--1.0%), and genotype 4 was 0.0% (95% CI: 0.0--0.1%).

Genotype 1 was more common among populations at high risk of healthcare-related exposures than genotype 3. Meanwhile, genotype 3 was more common among PWID than genotype 1. Within genotype 1, subtype 1a and subtype 1b were isolated (where subtype information was available) from 79.5% and 20.5% of individuals, respectively.

Quality assessment {#Sec22}
------------------

The results of the quality assessment are summarized in Table [5](#Tab5){ref-type="table"}. The majority of HCV incidence measures (60%) were based on samples with \>100 participants, and therefore were classified as having high precision. Incidence studies were based on convenience sampling from clinical facilities, and 60% had a response rate \>80%. All incidence measures were based on biological assays.Table 5Summary of precision and risk of bias (ROB) assessment for the hepatitis C virus (HCV) incidence and prevalence measures extracted from eligible reports.Quality assessmentHCV incidenceHCV prevalencen%n%**Precision of estimates**High precision360.031277.4Low precision240.07919.6Unclear^a^123.0**Risk of bias quality domains** **HCV ascertainment**Low risk of bias5100402100High risk of bias0000**Sampling methodology**Low risk of bias004811.9High risk of bias510035087.1Unclear0041.0**Response rate**Low risk of bias360.037092.0High risk of bias240.0102.5Unclear^a^00225.5**Total studies where risk of bias assessment was possible510040299.8Unknown** ^b^000.2**Total studies5100403100Summary of risk of bias assessment for HCV prevalence measuresn%Low risk of bias**In at least one quality domain402100In at least two quality domains37192.3In all three quality domains4711.7**High risk of bias**In at least one quality domain35087.1In at least two quality domains102.5In all three quality domains00**Total studies where risk of bias assessment was possible40299.8Total studies403100**^a^Studies with missing information for any of the domains were classified as having unclear risk of bias for that specific domain.^b^Studies extracted through country-level routine reporting with limited description of the sample (not permitting the conduct of risk of bias assessment) were classified as being of unknown quality.

The majority of HCV prevalence measures (77.4%) were based on samples with \>100 participants, and therefore were classified as having high precision. Of the 403 prevalence measures, ROB assessment was possible for 402 measures.

All HCV prevalence measures were based on biological assays. In 25.0% of measures, information on the exact biological assay was missing. Approximately one third of the samples underwent secondary confirmatory testing, with the majority using the more sensitive and specific recombinant immunoblot assay (RIBA). Among studies where information was available on assay generation, the majority (71.2%) used the more recent, sensitive, and specific 3rd generation Enzyme-linked immunosorbent assay (ELISA) tests, and 26.9% used 2^nd^ generation ELISA. The majority of samples (82.6%) were drawn using non-probability based sampling. Response rate was high in 92.0% of studies.

In summary, HCV prevalence measures were of reasonable quality. All studies had a low ROB in at least one quality domain, 92.3% had a low ROB in at least two of the three quality domains, and 11.7% had a low ROB in all three quality domains. Only 2.5% of studies had a high ROB in two of the three quality domains, and no study had a high ROB in all three quality domains.

Meta-regressions and sources of heterogeneity {#Sec23}
---------------------------------------------

The results of our meta-regression models can be found in Table [6](#Tab6){ref-type="table"}. The univariable meta-regression analyses identified population, study site, sample size, and year of data collection as significant predictors (with p \< 0.1), and therefore eligible for inclusion in the final multivariable meta-regression model. Sampling methodology used (probability-based or nonprobability-based) was not associated with HCV prevalence (p \> 0.1). In the final multivariable meta-regression analysis, all variables remained statistically significant (p \< 0.05) with the exception of healthcare setting and unspecified study site. The final multivariable model explained 71.7% of the variability in HCV prevalence. Of note, the model indicated a statistically significant declining trend in HCV prevalence in Iran---year of data collection had an AOR of 0.93 (95% CI: 0.91--0.96).Table 6Univariable and multivariable meta-regression models for the mean HCV prevalence among populations in Iran.Number of studiesUnivariable analysisMultivariable analysis^a^OR (95% CI)p-valueAOR (95% CI)p-valuePopulation classificationGeneral population (low risk)1221---1---PWID56269.41 (175.01--414.72)0.00088.80 (52.30--150.75)0.000HIV patients25273.98 (152.38--492.64)0.000135.48 (72.30--253.87)0.000Populations at high risk of healthcare-related exposures12748.08 (34.26--67.46)0.00039.33 (25.69--60.20)0.000Populations at intermediate risk7010.10 (6.76--15.10)0.0004.36 (2.74--6.94)0.000Populations with liver-related conditions2816.34 (9.34--28.61)0.00010.24 (5.65--18.55)0.000Other special clinical populations447.22 (4.51--11.55)0.0006.01 (3.61--10.02)0.000Study siteCommunity421---1---Blood bank730.31 (0.15--0.64)0.0020.45 (0.7--0.77)0.003Prison4428.12 (12.6--62.71)0.0003.66 (2.05--6.52)0.000Rehab/Drop-in-center3548.49 (20.71--113.56)0.0002.26 (1.19--4.33)0.013Healthcare setting2565.72 (3.08--10.62)0.0000.64 (0.40--1.02)0.063Unspecified223.74 (1.41--9.96)0.0081.11 (0.56--2.18)0.766Sampling methodologyProbability-based521---1---Nonprobability-based3901.7 (0.88--3.46)0.114------Unspecified301.81 (0.62--5.26)0.274------Sampling size\<1001441---1---≥1003280.28 (0.18--0.44)0.0000.70 (0.53--0.92)0.010Year of data collection4720.95 (0.90--1.00)0.0320.93 (0.91--0.96)0.000Year of publication4721.00 (0.91--1.02)0.150------^a^The adjusted R-square for the full model was 71.74%. Abbreviations: OR= Odds ratio; AOR= Adjusted odds ratio; CI = Confidence interval; PWID = People who inject drugs.

Discussion {#Sec24}
==========

We presented a comprehensive systematic review and synthesis of HCV epidemiology in Iran. The pooled mean HCV prevalence in the general population was estimated at only 0.3%, on the lower side of the levels observed in other MENA countries^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^ and globally^[@CR75]--[@CR77]^. Despite this low prevalence in the general population, high prevalence was found among PWID and populations at high risk of healthcare-related exposures. These findings suggest that most ongoing HCV transmission in Iran is driven by injecting drug use and specific healthcare-related exposures. Genotypes 1 and 3 were the most frequently circulating strains. Of note, HCV prevalence in Iran is on a declining trend (Table [6](#Tab6){ref-type="table"}).

Our estimate for the general population is slightly lower than an estimate provided for the whole adult population as part of a global estimation using a different methodology---0.3% in our study versus 0.5% in *Gower et al*.^[@CR78]^. The difference may be explained by the fact that our estimate is strictly for the general (normally healthy) population. Moreover, our estimate is a pooled estimate of 122 studies as opposed to *Gower's et al*. estimate which was based on five studies^[@CR78]^. Inclusion of blood donor studies in our estimation did not explain the difference---our sensitivity analysis showed that estimated HCV prevalence in the general population was invariable with exclusion of blood donors (Fig. [S5](#MOESM1){ref-type="media"}).

Iran has one of the highest population proportion of current PWID in the adult population (0.43%) in MENA, with an estimate of 185,000 current PWID^[@CR16],[@CR79]^. Our synthesis indicated that injecting drug use was one of the most commonly reported risk factors for HCV infection, and that the pooled mean HCV prevalence among PWID was 52.2% (Table [4](#Tab4){ref-type="table"}). These results suggest that injecting drug use is a main driver, if not the main driver, of HCV incidence in this country (Table [6](#Tab6){ref-type="table"}). The regional context of Iran and the drug trafficking routes^[@CR21],[@CR80],[@CR81]^, support an environment of active injection and a major role for PWID in HCV transmission. In this regard, HCV epidemiology in Iran appears to resemble that in developed countries, such as in the United States of America (USA), where most HCV incidence is attributed to drug injection^[@CR17],[@CR82],[@CR83]^. Of note, we identified high HCV prevalence even among drug users where the route of drug use was not specified or excluded drug injection. This may suggest under-reporting of drug injection among those who report just drug use, or past drug injection among them before shifting to other forms of drug use.

Having said so, the estimated low HCV prevalence in the general population of only 0.3% apparently contradicts with a large PWID population in Iran. In the USA, it is estimated that the population proportion of current PWID is 0.3%^[@CR84]^, and that of lifetime PWID is 2.6%^[@CR84]^, compared to 0.43% for current PWID in Iran^[@CR16]^. HCV prevalence among PWID in the USA is just over 50%^[@CR85]^, therefore comparable with the pooled estimate of 52.2% for PWID in Iran (Table [4](#Tab4){ref-type="table"}). HCV prevalence in the wider adult population in the USA is estimated at 1.0%^[@CR86]^, much higher than the pooled estimate for HCV prevalence in the general population in Iran (0.3%). This discrepancy may be explained by an over-estimated current PWID population in Iran, very recent trend of drug injection with relatively small lifetime PWID population, or that the estimated HCV prevalence in the general population considerably underestimates the actual HCV prevalence in the whole adult population in Iran.

Our synthesis suggests that prisons have been a major setting for HCV transmission in Iran (Table [6](#Tab6){ref-type="table"}). With nearly 60% of prisoners being incarcerated for drug-related offences^[@CR81]^, high reported injecting risk behaviors in prisons^[@CR16],[@CR28]^, and the high HCV prevalence among prisoners (Tables [3](#Tab3){ref-type="table"} and [S2](#MOESM1){ref-type="media"}), prisons should be a main focus of HCV prevention and treatment efforts. Iran has made major and internationally-recognized strides in establishing harm reduction services for PWID including in prisons^[@CR16],[@CR33],[@CR87]--[@CR90]^, but further scale-up of these services in all prisons is warranted.

High HCV prevalence was found in populations at high risk of healthcare-related exposures such as hemodialysis, hemophilia, and thalassemia patients, though with geographical variation (Tables [3](#Tab3){ref-type="table"} and [6](#Tab6){ref-type="table"}). This finding, along with the higher HCV prevalence generally among clinical populations (Table [S3](#MOESM1){ref-type="media"}), suggests that healthcare is also a main driver of HCV transmission, though less so than in most other MENA countries^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^. The quality of healthcare and application of stringent protocols for infection control appear also to vary by setting within Iran. Overall, however, Iran seems to have made major progress in reducing HCV exposures through healthcare, which may explain the declining trend in HCV prevalence (Table [6](#Tab6){ref-type="table"})^[@CR91]--[@CR93]^. For example, HCV prevalence among hemodialysis patients was reported in one study to have declined from 14.4% in 1999 to 4.5% in 2006^[@CR94]^.

HCV genotype 1 was the dominant circulating strain in Iran (56% of infections), followed by genotype 3 (39% of infections). This shows similarity to the pattern observed in multiple countries globally^[@CR95]^. Nevertheless, this genotype distribution differs substantially from that found in most other MENA countries^[@CR29]^. Several recent studies have also indicated an increasing presence of genotype 3^[@CR96],[@CR97]^. This shift may be due to the fact that injecting drug use is a major driver of HCV incidence^[@CR29],[@CR98]^ (Table [6](#Tab6){ref-type="table"}), or the fact that this is a sub-regional pattern---genotype 3 is the main circulating strain in neighboring Pakistan^[@CR29]^.

Our meta-analyses confirmed high heterogeneity in estimated effect sizes (Table [4](#Tab4){ref-type="table"}). This was expected, due to differences between studies in variables such as risk population, study site, sampling methodology, sample size, and year of data collection, among others. Our meta-regressions identified several sources of heterogeneity in HCV prevalence studies in Iran. As expected, large differences in HCV prevalence by risk population were observed (Table [6](#Tab6){ref-type="table"}). A small-study effect was also observed, with small studies reporting higher HCV prevalence. Importantly, a time trend was also observed with a declining HCV prevalence with time.

Our study is limited by the quality of available studies, as well as their representativeness of the different risk populations. High heterogeneity in prevalence measures were identified in all meta-analyses for all risk populations (Table [4](#Tab4){ref-type="table"}). Meta-regression analyses were performed to identify the sources of heterogeneity, and while the final multivariable regression model accounted for 71.7% of observed heterogeneity, there are variables that we are unable to assess, such as "hidden" selection bias in recruitment.

Another limitation is the absence of reporting of the specific used biological assay in 25.0% of studies. The majority of included studies were based on convenience sampling. Although this is presumed a limitation, the meta-regression analyses did not identify sampling methodology as a statistically significant source of heterogeneity in HCV prevalence (p = 0.114; Table [6](#Tab6){ref-type="table"}).

Despite these limitations, the main strength of our study is that we identified a very large number of studies, in fact the largest of all MENA countries^[@CR7],[@CR9],[@CR21]--[@CR25],[@CR27]^, that covered all risk populations and that allowed us to have such a comprehensive synthesis of HCV epidemiology.

Conclusions {#Sec25}
===========

HCV prevalence in the wider population in Iran appears to be considerably below 1%---on the lower range compared to HCV prevalence in other MENA countries and globally. However, high HCV prevalence was found among PWID and populations at high risk of healthcare-related exposures. Most ongoing HCV transmission appears to be driven by injecting drug use and specific healthcare-related exposures. Genotypes 1 and 3 were the most frequently circulating strains.

There are still gaps in our understanding of HCV epidemiology in this country. Conduct of a nationally-representative population-based survey is strongly recommended to provide a better estimate of HCV prevalence in the whole population, delineate the spatial variability in prevalence, identify specific modes of exposure, and assess HCV knowledge and attitudes, as has been recently conducted in Egypt^[@CR10],[@CR99]--[@CR103]^ and Pakistan^[@CR6],[@CR15],[@CR104]^.

Our study informs planning of health service provision, development of policy guidelines, and implementation of HCV prevention and treatment programming to reduce HCV transmission and decrease the burden of its associated diseases. Our findings suggest the need of a targeted approach to HCV control based on settings of exposure. Iran has established internationally-celebrated harm reduction services for PWID^[@CR16],[@CR87]--[@CR90],[@CR105]^, but these services need to be accessible to all PWID across the country, as well as in relevant settings, such as prisons. Further focus on infection control in healthcare facilities is also warranted, such as the adoption of the new WHO guidelines for the use of safety-engineered syringes^[@CR106],[@CR107]^.
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